Squamous Cell Carcinoma Of The Head And Neck – Unmet Need – Detailed, Expanded Analysis: Squamous Cell Carcinoma Of The Head And Neck (US/EU) 2022

The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (SCCHN) patients in the first-line recurrent or metastatic setting. The approval of immune checkpoint inhibitors—Keytruda (Merck & Co.) and Opdivo (Bristol-Myers Squibb)—in the first-line setting over the last decade has changed the treatment paradigm for recurrent or metastatic SCCHN patients as monotherapy and/or in combination with platinum + 5-FU. However, there is a strong need for effective therapies in this patient setting. This report provides a detailed analysis of the factors that influence medical oncologists' prescribing decisions and reviews the unmet needs that novel therapies should confront.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in medical oncologists’ prescribing decisions for non-nasopharyngeal SCCHN?
  • How do current therapies, such as immune checkpoint inhibitors, perform on key treatment drivers and goals for this patient population?
  • What are the prevailing areas of unmet need and hidden opportunity that drug developers could leverage in the treatment of non-nasopharyngeal SCCHN?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical target product profile for non-nasopharyngeal SCCHN?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 33 European medical oncologists fielded in December 2021

Key companies: Merck & Co., Bristol Myers Squibb, Eli Lilly

Key drugs: Erbitux, Keytruda, Opdivo

Table of contents

  • Squamous Cell Carcinoma Of The Head And Neck - Unmet Need - Detailed, Expanded Analysis: Squamous Cell Carcinoma Of The Head And Neck (US/EU) 2022
    • Executive summary
      • Unmet Need - Recurrent or Metastatic Non-Nasopharyngeal SCCHN - Executive Summary - March 2021
    • Introduction
      • Overview
      • Methodology
      • Rationale for treatment drivers and goals selection
        • Rationale for drug selection
          • Products / regimens for recurrent or metastatic non-nasopharyngeal SCCHN and rationale for drug selection
      • Treatment drivers and goals
        • Key findings: attribute importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN
        • Importance of efficacy attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
        • Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
        • Importance of safety and tolerability attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
        • Importance of convenience of administration attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
        • Key findings: stated vs. derived importance
        • Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: United States
        • Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
      • Product performance against treatment drivers and goals
        • Key findings
        • Overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States
        • Overall Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
        • Mean overall performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN: United States and Europe
        • Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: United States
        • Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select efficacy attributes: Europe
        • Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Safety and Tolerability Attributes: United States
        • Relative performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN across select safety and tolerability attributes: Europe
        • Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN Across Select Convenience of Administration Attributes: Europe
      • Assessment of unmet need
        • Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN
        • Surveyed Medical Oncologistsu2019 Satisfaction with the Performance of Key Therapies for Recurrent or Metastatic Non-Nasopharyngeal SCCHN on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed medical oncologistsu2019 satisfaction with the performance of key therapies for recurrent or metastatic non-nasopharyngeal SCCHN on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: United States
        • Surveyed medical oncologists' ascribed level of unmet need across key safety and tolerability attributes in recurrent or metastatic non-nasopharyngeal SCCHN: Europe
        • Surveyed medical oncologists' ascribed level of unmet need across key convenience of administration attributes in recurrent or metastatic non-nasopharyngeal SCCHN: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Recurrent or Metastatic Non-Nasopharyngeal SCCHN: Europe
        • Key findings: unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Recurrent or Metastatic Non-Nasopharyngeal SCCHN and Related Indications: United States
        • Surveyed medical oncologists' ascribed level of unmet need in recurrent or metastatic non-nasopharyngeal SCCHN and related indications: Europe
      • Opportunity analysis
        • Areas of opportunity in the recurrent or metastatic non-nasopharyngeal SCCHN market and emerging therapy insights
          • Opportunity: a novel therapy offering a substantial overall survival benefit
          • Opportunity: a novel therapy offering an improved and durable response
          • Opportunity: a novel therapy offering an improved quality of life
      • Target product profiles
        • Assessing drug development opportunities
        • Target product profile methodology
          • Attributes and attribute levels
        • Attribute importance and part-worth utilities
          • First-line recurrent or metastatic non-nasopharyngeal SCCHN target product profile: attribute importance
          • Median overall survival (months)
          • Median progression-free survival (months)
          • Objective response rate (% of patients)
          • Incidence of grade 3/4 hematological toxicities (% of patients)
          • Incidence of grade 3/5 immune-mediated adverse events (% of patients)
          • Quality of life (Global Health Status / QLQ-30 Score)
          • Price per 21-day cycle
        • Conjoint analysis-based simulation of a market scenario
          • First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: share of preference of target product profiles Included in the market scenario
          • First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: likelihood to prescribe target product profiles included in the market scenario
          • First-line recurrent or metastatic non-nasopharyngeal SCCHN market simulation: target product profiles included in the market scenario
      • Appendix
        • Bibliography

    Login to access report

    launch Related Market Assessment Reports